These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

749 related articles for article (PubMed ID: 31851193)

  • 1. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
    Kolyadina IV; Zavalishina LE; Ganshina IP; Andreeva YY; Frank GA; Gordeeva OO; Zhukova LG; Meshcheryakov AA; Savelov NA; Tuzova EA; Morozov DA; Poddubnaya IV
    Arkh Patol; 2019; 81(6):56-62. PubMed ID: 31851193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
    Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
    Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.
    Murthy RK; Raghavendra AS; Hess KR; Fujii T; Lim B; Barcenas CH; Zhang H; Chavez-Mac-Gregor M; Mittendorf EA; Litton JK; Giordano SH; Thompson AM; Valero V; Moulder SL; Tripathy D; Ueno NT
    Clin Breast Cancer; 2018 Dec; 18(6):e1283-e1288. PubMed ID: 30077429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant pertuzumab plus trastuzumab in combination with anthracycline- free chemotherapy regimen in patients with HER2 positive breast cancer-Real-world data from a single center in India.
    Arora S; Gogia DA; Deo S; Sharma D; Mathur SR
    Cancer Treat Res Commun; 2021; 29():100483. PubMed ID: 34710849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for HER2-positive breast cancer: a prospective cohort study.
    Liu L; Zhu M; Wang Y; Li M; Gu Y
    World J Surg Oncol; 2023 Dec; 21(1):389. PubMed ID: 38114991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
    González-Santiago S; Saura C; Ciruelos E; Alonso JL; de la Morena P; Santisteban Eslava M; Gallegos Sancho MI; de Luna A; Dalmau E; Servitja S; Ruiz Borrego M; Chacón JI
    Breast Cancer Res Treat; 2020 Nov; 184(2):469-479. PubMed ID: 32876911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter analysis of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive breast cancer.
    Echavarria I; Granja M; Bueno C; Lopez-Tarruella S; Peinado P; Sotelo M; Jerez Y; Moreno F; Torres G; Lobo M; Marquez-Rodas I; Del Monte-Millan M; Martín M; García-Saenz JA
    Breast Cancer Res Treat; 2017 Feb; 162(1):181-189. PubMed ID: 28040858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegylated Liposomal Doxorubicin, Docetaxel, and Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer Patients: A Phase II and Biomarker Study.
    Wang H; Li Y; Qi Y; Zhao E; Kong X; Yang C; Yang Q; Zhang C; Liu Y; Song Z
    Front Oncol; 2022; 12():909426. PubMed ID: 35875123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world study of trastuzumab and pertuzumab combined with chemotherapy in neoadjuvant treatment for patients with HER2-positive breast cancer.
    Ma X; Zhang X; Zhou X; Ren X; Ma X; Zhang W; Yang R; Song T; Liu Y
    Medicine (Baltimore); 2022 Oct; 101(40):e30892. PubMed ID: 36221359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
    Choi JH; Jeon CW; Kim YO; Jung S
    Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
    van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
    Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
    de Haas SL; Slamon DJ; Martin M; Press MF; Lewis GD; Lambertini C; Prat A; Lopez-Valverde V; Boulet T; Hurvitz SA
    Breast Cancer Res; 2023 Jan; 25(1):2. PubMed ID: 36631725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
    Saracchini S; Foltran L; Tuccia F; Bassini A; Sulfaro S; Micheli E; Del Conte A; Bertola M; Gion M; Lorenzon M; Tumolo S
    Breast; 2013 Dec; 22(6):1101-7. PubMed ID: 24074879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study.
    Lopresti ML; Bian JJ; Sakr BJ; Strenger RS; Legare RD; Fenton M; Witherby SM; Dizon DS; Pandya SV; Stuckey AR; Edmondson DA; Gass JS; Emmick CM; Graves TA; Cutitar M; Olszewski AJ; Sikov WM
    Breast Cancer Res Treat; 2021 Aug; 189(1):93-101. PubMed ID: 34086171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
    Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
    Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer.
    Sánchez-Muñoz A; Navarro-Perez V; Plata-Fernández Y; Santonja A; Moreno I; Ribelles N; Alba E
    Clin Breast Cancer; 2015 Oct; 15(5):343-7. PubMed ID: 25752727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years.
    Kolberg HC; Akpolat-Basci L; Stephanou M; Aktas B; Hannig CV; Liedtke C
    Breast Care (Basel); 2016 Oct; 11(5):323-327. PubMed ID: 27920624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
    von Minckwitz G; Colleoni M; Kolberg HC; Morales S; Santi P; Tomasevic Z; Zhang N; Hanes V
    Lancet Oncol; 2018 Jul; 19(7):987-998. PubMed ID: 29880292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
    Lavasani SM; Somlo G; Yost SE; Frankel PH; Ruel C; Cui Y; Murga M; Tang A; Martinez N; Kruper L; Tumyan L; Schmolze D; Yeon C; Yuan Y; Waisman JR; Mortimer J
    Cancer; 2023 Mar; 129(5):740-749. PubMed ID: 36517940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.